Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells
Background The sensitivity of non-small cell lung cancer (NSCLC) patients to EGFR tyrosine
kinase inhibitors (TKIs) is strongly associated with activating EGFR mutations. Although not …
kinase inhibitors (TKIs) is strongly associated with activating EGFR mutations. Although not …
Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant …
Epidermal growth factor receptor (EGFR), an aberrantly overexpressed or activated receptor-
tyrosine kinase in many cancers, plays a pivotal role in cancer progression and has been an …
tyrosine kinase in many cancers, plays a pivotal role in cancer progression and has been an …
Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer
EM Tricker, C Xu, S Uddin, M Capelletti, D Ercan… - Cancer discovery, 2015 - AACR
Irreversible pyrimidine-based EGFR inhibitors, including WZ4002, selectively inhibit both
EGFR-activating and EGFR inhibitor–resistant T790M mutations more potently than wild …
EGFR-activating and EGFR inhibitor–resistant T790M mutations more potently than wild …
Inhibition of ABCB1 overcomes cancer stem cell–like properties and acquired resistance to MET inhibitors in non–small cell lung cancer
T Sugano, M Seike, R Noro, C Soeno, M Chiba… - Molecular cancer …, 2015 - AACR
Patients with non–small cell lung cancer (NSCLC) EGFR mutations have shown a dramatic
response to EGFR inhibitors (EGFR-TKI). EGFR T790M mutation and MET amplification …
response to EGFR inhibitors (EGFR-TKI). EGFR T790M mutation and MET amplification …
Mechanisms of resistance to EGFR targeted therapies
G Hrustanovic, BJ Lee, TG Bivona - Cancer biology & therapy, 2013 - Taylor & Francis
EGFR is a validated therapeutic target in many human cancers. EGFR targeted therapies
are in widespread clinical use in patients with non-small cell lung cancer and other tumor …
are in widespread clinical use in patients with non-small cell lung cancer and other tumor …
[HTML][HTML] Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation
M Zou, S Xia, L Zhuang, N Han… - International …, 2013 - spandidos-publications.com
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are being widely
used as targeted therapy in non-small cell lung cancer (NSCLC), but most cases acquire …
used as targeted therapy in non-small cell lung cancer (NSCLC), but most cases acquire …
Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells
K Tabara, R Kanda, K Sonoda, T Kubo, Y Murakami… - PLoS …, 2012 - journals.plos.org
Non-small-cell lung cancer harboring epidermal growth factor receptor (EGFR) mutations
attains a meaningful response to EGFR-tyrosine kinase inhibitors (TKIs). However, acquired …
attains a meaningful response to EGFR-tyrosine kinase inhibitors (TKIs). However, acquired …
Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer
S Raoof, IJ Mulford, H Frisco-Cabanos, V Nangia… - Oncogene, 2019 - nature.com
Evolved resistance to tyrosine kinase inhibitor (TKI)-targeted therapies remains a major
clinical challenge. In epidermal growth factor receptor (EGFR) mutant non-small-cell lung …
clinical challenge. In epidermal growth factor receptor (EGFR) mutant non-small-cell lung …
Amplification of EGFR wild-type alleles in non–small cell lung cancer cells confers acquired resistance to mutation-selective EGFR tyrosine kinase inhibitors
S Nukaga, H Yasuda, K Tsuchihara, J Hamamoto… - Cancer research, 2017 - AACR
EGFR-mutated lung cancers account for a significant subgroup of non–small cell lung
cancers overall. Third-generation EGFR tyrosine kinase inhibitors (TKI) are mutation …
cancers overall. Third-generation EGFR tyrosine kinase inhibitors (TKI) are mutation …
[HTML][HTML] EGFR-TKI resistance in NSCLC patients: mechanisms and strategies
Y Lin, X Wang, H Jin - American journal of cancer research, 2014 - ncbi.nlm.nih.gov
The epidermal growth factor receptor (EGFR) is a kind of receptor tyrosine kinase (RTK) that
plays a critical role in the initiation and development of malignant tumors via modulating …
plays a critical role in the initiation and development of malignant tumors via modulating …